MYELOFIBROSIS

This study is testing a modified, gentler two-step method to prepare patients for a stem cell transplant. The goal is to reduce the risk of death from the transplant procedure itself for people with various blood cancers and disorders. Researchers are comparing two lower-intensit…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study is testing an investigational drug called KER-050 (elritercept) to see if it is safe and can help people with myelofibrosis, a serious bone marrow cancer. The drug is designed to help the body make more red blood cells and platelets, which could reduce anemia and other…

This early study is testing if a drug called Darzalex Faspro can safely lower harmful antibodies in patients with blood cancers. Lowering these antibodies may allow patients who are currently ineligible to receive a potentially life-saving stem cell transplant from a donor. The s…

This study is testing if Nelfinavir, a drug originally used for HIV, can help treat anemia in people with myelofibrosis, a rare bone marrow cancer. Researchers want to see if the drug helps restore iron to the bone marrow to improve red blood cell counts and reduce scarring. The …

This study is for people with myelofibrosis, a serious bone marrow cancer, who are not getting the best results from their current standard medication (ruxolitinib). It will test if adding a new drug called navtemadlin to the standard treatment works better and is safe. About 600…

This early-stage study is testing a new drug called imetelstat when given alongside an existing drug, ruxolitinib, for people with myelofibrosis, a serious bone marrow cancer. The main goals are to find a safe dose and see if the combination helps reduce symptoms like fatigue and…

This study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study i…

This study is testing a medical device called MEX-CD1 that works like dialysis to filter excess iron from the blood. It is for patients with myelodysplastic syndrome or myelofibrosis who need regular blood transfusions, which cause dangerous iron buildup, but who cannot tolerate …

This is the first study in people to test a new drug called JNJ-88549968 for blood cancers with a specific genetic change (CALR mutation). The main goals are to find a safe dose and understand how the body handles the drug. The drug works by guiding a patient's own immune cells t…

This study is testing an experimental drug called DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who have anemia. The main goals are to see if the drug is safe and if it can help improve red blood cell counts, potentially reducing or eliminating the need for b…

This program provides the investigational drug selinexor to patients with certain cancers who have run out of standard treatment options and don't qualify for ongoing clinical trials. It allows doctors to request the drug for eligible patients before it receives full regulatory a…

This study is testing whether adding a new drug called ulixertinib to an existing medication (ruxolitinib) is safe and effective for people with myelofibrosis, a rare bone marrow cancer. Researchers will enroll 37 adults who are already taking ruxolitinib but still have significa…

This study is testing a combination of two new drugs, TQ05105 and TQB3617, for people with intermediate- or high-risk myelofibrosis, a rare bone marrow cancer. The main goals are to find the safest and most effective dose and to see if the treatment can shrink enlarged spleens an…

This early-stage study aims to find the safest and most tolerable dose of an investigational drug called momelotinib for people with myelofibrosis, a serious bone marrow cancer. It will involve up to 28 patients who are already scheduled to receive a stem cell transplant, a stand…

This study is testing a new oral medication called nuvisertib for people with intermediate or high-risk myelofibrosis, a serious bone marrow cancer. It aims to find a safe dose and see if the drug can reduce spleen size and ease symptoms. The trial is enrolling about 240 patients…

This study aims to find the best drug combination to prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Researchers are comparing two new drug combinations against the current standard …

This study is testing a new drug, RVU120, given alone or with an existing drug (ruxolitinib), for adults with intermediate or high-risk myelofibrosis, a serious bone marrow cancer. The main goal is to see if the treatment can shrink enlarged spleens and improve symptoms in patien…

This study is testing whether giving a high dose of the drug ruxolitinib, along with busulfan chemotherapy, before a stem cell transplant can help shrink an enlarged spleen and make the transplant more successful for people with myelofibrosis. Researchers will enroll about 30 pat…

This study is testing whether the drug selinexor can reduce spleen size and ease symptoms in people with myelofibrosis, a type of bone marrow cancer, who also have low platelet counts and have not yet taken common JAK inhibitor drugs. About 58 participants will take selinexor alo…

This study is testing if a new type of imaging scan (called 18F-FAPI PET/MRI) can be used to diagnose and monitor myelofibrosis, a serious bone marrow disease. Researchers want to see if this scan is as good as or better than the current painful bone marrow biopsy, which cannot b…

This early-stage trial is testing a new vaccine designed to prevent serious cytomegalovirus (CMV) infections. The study involves patients with blood cancers who are receiving a stem cell transplant from a partially matched donor, a procedure that carries a high risk of CMV. Resea…

This study is testing a new vaccine approach to prevent a common and serious viral infection called CMV in patients receiving a stem cell transplant for blood cancers. Researchers are giving the vaccine to the healthy stem cell donors, hoping the donor's boosted immunity will be …

This study aims to find the best dose of N-Acetylcysteine (N-AC), a common supplement, to help reduce symptoms in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It will enroll 27 adults with ET, PV, or MF who have significant symptom burden. The main g…

This study is testing whether a telehealth program helps older patients with serious blood cancers have better conversations with their doctors about future care wishes. It aims to see if these structured video calls reduce patient anxiety and distress, and help more people compl…

This study is testing whether a curcumin supplement, the active ingredient in turmeric, can reduce inflammation and improve symptoms in people with certain blood cell disorders. Researchers will compare the supplement to a placebo in 30 participants over 12 months. The main goals…

This study is testing a new artificial intelligence (AI) tool designed to help match people with advanced cancer to suitable clinical trials. It will enroll up to 50,000 patients to see if using this AI system makes it easier for patients to find and join trials. The researchers …

This study aims to better understand a specific genetic mutation (ASXL1) found in a blood cancer called myelofibrosis. Researchers will observe 50 adult patients over 4 years to see how different patterns of this mutation relate to survival and the risk of the disease worsening. …

This study aims to gather detailed information on how myelofibrosis, a rare and serious bone marrow cancer, affects patients in everyday clinical practice. It will follow over 600 patients across Europe for several years, tracking their health, treatments, and quality of life. Th…

This is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …